Biogen Inc.
🏢 View company profile →137Patents
10Active
137Granted
42Portfolio score
Filing activity: Jan 10, 1985 → Jul 30, 2019 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4873316A | Isolation of exogenous recombinant proteins from the milk of transgenic mammals | Emerging Cross-Sectional Technologies | 468 | Expired |
| US5561236A | Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants | Emerging Cross-Sectional Technologies | 241 | Expired |
| US5109124A | Nucleic acid probe linked to a label having a terminal cysteine | Human Necessities | 215 | Expired |
| US5804604A | Tat-derived transport polypeptides and fusion proteins | Chemistry; Metallurgy | 210 | Expired |
| US7112665B1 | Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants | Emerging Cross-Sectional Technologies | 167 | Expired |
| US6316003A | Tat-derived transport polypeptides | Chemistry; Metallurgy | 82 | Expired |
| US4956281A | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 | Human Necessities | 71 | Expired |
| US6602503B1 | Recombinant anti-VLA-4 antibody molecules | Chemistry; Metallurgy | 71 | Expired |
| US6162432A | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction | Chemistry; Metallurgy | 66 | Expired |
| US5169936A | Protein purification on immobilized metal affinity resins effected by elution using a weak ligand | Chemistry; Metallurgy | 64 | Expired |
| US4956288A | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA | Chemistry; Metallurgy | 63 | Expired |
| US5196404A | Inhibitors of thrombin | Emerging Cross-Sectional Technologies | 56 | Expired |
| US5272263A | DNA sequences encoding vascular cell adhesion molecules (VCAMS) | Emerging Cross-Sectional Technologies | 47 | Expired |
| US5932214A | Treatment for inflammatory bowel disease with VLA-4 blockers | Chemistry; Metallurgy | 44 | Expired |
| US5359032A | Interkeukin-1 inhibitor | Human Necessities | 43 | Expired |
| US6664385B1 | Kidney injury-related molecules | Chemistry; Metallurgy | 42 | Expired |
| US5240913A | Inhibitors of thrombin | Human Necessities | 40 | Expired |
| US6338953B1 | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein | Chemistry; Metallurgy | 39 | Expired |
| US5256559A | Methods and compositions for inhibiting platelet aggregation | Human Necessities | 39 | Expired |
| US5925351A | Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease | Emerging Cross-Sectional Technologies | 39 | Expired |
| US6800735B2 | Interferon-beta fusion proteins and uses | Chemistry; Metallurgy | 38 | Expired |
| US5888507A | Treatment for insulin dependent diabetes | Chemistry; Metallurgy | 38 | Expired |
| US5487984A | Processes for producing tumor necrosis factor | Emerging Cross-Sectional Technologies | 37 | Expired |
| US5168049A | Production of streptavidin-like polypeptides | Chemistry; Metallurgy | 36 | Expired |
| US5871734A | Treatment for asthma with VLA-4 blocking agents | Chemistry; Metallurgy | 36 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.